Navigation Links
Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
Date:1/10/2011

SAN DIEGO, Jan. 10, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the appointment of Dr. Hank McKinnell to its Board of Directors.  Dr. McKinnell is the former Chief Executive Officer and former Chairman of the Board of Directors of Pfizer Inc.  He is currently Chairman of the Accordia Global Health Foundation, an organization dedicated to fighting infectious diseases in Africa, and is a member of the boards of Moody's Corporation, Angiotech Pharmaceutical, Inc., and privately-held Emmaus Medical, Inc.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

"Hank McKinnell's extensive business experience, deep interest in the opportunities of the biotech industry, and dedication to profound social advances to health and wellness for patients globally makes him a valuable addition to Optimer's Board of Directors," said Pedro Lichtinger, President and CEO of Optimer. "Our ability to attract someone with Hank's business acumen and demonstrated leadership talent is an inspiration to our team. His experience in economics, strategy and business operations has been instrumental in pioneering an approach for marrying innovation, health and wellness and market access as the essential formula for success in today's pharmaceutical marketplace.  We at Optimer will benefit from his tremendous skillset and insights."

"Optimer has a unique opportunity to drive some of the most exciting innovation in health care," said Dr. McKinnell.  "Fidaxomicin is a cutting edge antibiotic for c.diff, a bacterial infection putting increasing pressure on hospitals and placing the sick and elderly at particular risk, and addresses a growing health challenge with the aging of our population – especially as the first of the Baby Boomers turn 65 this Jan
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
(Date:1/15/2014)... MILTON, N.Y. , Jan. 15, 2014 Sono-Tek Corporation ... three months ended November 30, 2013, compared to sales of ... or 20%. Once again, this quarter has also shown growth ... in the first quarter of this fiscal year. Markets that ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... its Medical Software Advice website ( www.softwareadvice.com/medical ), a ... the right technology for their practices. , , ,"The ... vendor landscape is more fragmented than ever," said Don ... "We aim to bring clarity to the market ...
... 17 Schering-Plough,Corporation (NYSE: SGP ) today ... a fast-dissolving, sublingual tablet being,developed for treatment of ... in treating patients with acute schizophrenia., According ... and 10 mg twice,daily were both significantly more ...
Cached Medicine Technology:Physicians Will Benefit from Medical Software Advice Website 2New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 2New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 3New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 4
(Date:7/10/2014)... health record becomes widespread across the United States, due ... Act, the quantity of clinical data that will become ... increase. Additionally, experts in healthcare have become increasingly ... data for the purpose of gleaning insights that have ... a process that is known as big data. ...
(Date:7/10/2014)... Kristen Fischer HealthDay Reporter ... down may help ease the hot flashes that often accompany ... for more than 50 percent of menopausal women, said Dr. ... reproductive science at the Icahn School of Medicine at Mount ... women experience more than 10 hot flashes a day, and ...
(Date:7/10/2014)... felt better prepared to respond to an active shooter ... new study in the journal Prehospital and Disaster ... examine the EMS provider comfort level with respect to ... been neutralized or working with law enforcement personnel during ... School shooting, the Virginia Tech campus shooting, the 2009 ...
(Date:7/10/2014)... the "Mississippi baby" an infant seemingly cured of HIV ... remission of HIV infection in The New England Journal ... after more than two years of not taking antiretroviral therapy ... and researchers involved in the case. , "Certainly, ... child, the medical staff involved in the child,s care, and ...
(Date:7/10/2014)... Estonian-born Katerina Alba,s research at the University of Huddersfield ... the most popular emulsion-based food products such as ... is starting to gain an international profile for her ... and food science at the University and now she ... with her supervisor, Dr Vassilis Kontogiorgos, she is investigating ...
Breaking Medicine News(10 mins):Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:Active shooter training increases comfort level of emergency responders 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 3Health News:World interest in research work on the benefits of the Okra plant 2
... -- Health care coverage increased dramatically in parts of ... interventions were implemented to improve access to health care, ... new research by Brown University sociologist Susan E. Short ... findings appear in the December issue of Health ...
... More than half a million children in the U.S. ... suffer TBI often report headaches afterward, but little is known ... a significant new study, "Headache After Pediatric Traumatic Brain ... three and 12 months after mild, moderate or severe TBI ...
... of paid sick leave, contributed to higher risk of exposure ... U.S. during the 2009 H1N1 pandemic, according to a study ... senior associate director of the Maryland Center for Health Equity ... findings are published online ahead of print in the ...
... HealthDay Reporter , MONDAY, Dec. 5 (HealthDay News) -- ... nearly three times higher risk of having an autism ... used national birth data that included nearly 656,000 children ... 428,000 women. Using a national prescription drug registry, they ...
... 5 (HealthDay News) -- There,s been a large increase in the ... 2002, a trend that may help ease concerns about a predicted ... data and found that the number of RNs aged 23 to ... fewer than 110,000 by 1991 and remained low for the next ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... women in New Hampshire, which has high levels of arsenic ... arsenic through rice. The study, published in this ... did not look for any potential health problems. However, other ...
Cached Medicine News:Health News:Chinese health coverage increases with new government efforts 2Health News:Chinese health coverage increases with new government efforts 3Health News:Study finds headaches after traumatic brain injury highest in adolescents and girls 2Health News:Study finds headaches after traumatic brain injury highest in adolescents and girls 3Health News:Maryland study finds that US Hispanics were at greater risk for H1N1 flu during 2009 pandemic 2Health News:Fetal Exposure to Epilepsy Drug Might Raise Autism Risk: Study 2Health News:Fetal Exposure to Epilepsy Drug Might Raise Autism Risk: Study 3Health News:Good News for Those Worried About U.S. Nursing Shortage 2Health News:Study Sees Rice as Source of Arsenic Exposure 2Health News:Study Sees Rice as Source of Arsenic Exposure 3
... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ... size and angle required for large and ...
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
... The Series I Instrument program offers ... low profile, while maintaining strength and durability. ... pathology in tight joint spaces. Series I ... cutting tip style, size and angle required ...
... fast and effective resection of meniscal tears ... rim. The flat, crescent-shaped tip has an ... tightest joint spaces. Made in the U.S. ... engineering experience in arthroscopy hand instrument design ...
Medicine Products: